Biotechnology

116 articles in this category (Page 4 of 5)

Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2025-12-22 - Increase Confidence 7/10

Strong cash position and positive Phase 1/2 data for EDG-7500 converge with upcoming investor updates, signaling near-term upside potential.

Dec 22, 2025EWTX

Stock Weather AIBiotechnologyClinical Trials

Zenas BioPharma – 2025-12-22 - Increase Confidence 8/10

Strong cash position and positive trial data converge ahead of imminent Phase 3 readout, signaling near-term upside for ZBIO.

Dec 22, 2025ZBIO

Stock Weather AIBiotechnologyClinical Stage

Edgewise Therapeutics – 2025-12-19 - Increase Confidence 7/10

Strong cash reserves and advancing clinical pipeline signal near-term upside despite ongoing losses; Q4 data readouts act as catalyst.

Dec 19, 2025EWTX

Stock Weather AIBiotechnologyMergers & Acquisitions

Amicus Therapeutics – 2025-12-19 - increase Confidence 9/10

Strong revenue growth and resolved patent litigation meet a $14.50 acquisition offer above current price, signaling near-term upside.

Dec 19, 2025FOLD

Stock Weather AIBiotechnologyClinical-Stage Pharma

Disc Medicine, Inc. – 2025-12-19 - increase Confidence 6/10

Negative free cash flow and high leverage offset by strong analyst consensus and upcoming catalysts in hematologic drug development; stock likely to rise near-term on biotech sector momentum.

Dec 19, 2025IRON

Stock Weather AIBiotechnologyClinical-Stage Pharma

Olema Pharmaceuticals – 2025-12-19 - Increase Confidence 8/10

Negative free cash flow offset by strong analyst momentum and recent trial validation, signaling near-term upside for OLMA.

Dec 19, 2025OLMA

Stock Weather AIBiotechnologyClinical Trials

Insmed – 2025-12-18 - Increase Confidence 6/10

Despite negative free cash flow and a failed Phase 2 trial, FDA approval of Brinsupri and strong analyst sentiment signal near-term upside potential.

Dec 18, 2025INSM

Stock Weather AIBiotechnologyClinical Trials

Immunome – 2025-12-15 - increase Confidence 8/10

Positive Phase 3 trial data meets primary endpoint with high statistical significance, triggering revaluation despite negative free cash flow; stock poised for near-term upside.

Dec 15, 2025IMNM

Stock Weather AIBiotechnologyClinical-Stage Pharma

Olema Pharmaceuticals – 2025-12-15 - Increase Confidence 7/10

Strong analyst consensus and robust cash reserves support upside, with palazestrant Phase 3 momentum acting as a near-term catalyst for OLMA.

Dec 15, 2025OLMA

Stock Weather AIBiotechnologyClinical-Stage Pharma

Centessa Pharmaceuticals – 2025-12-11 - Increase Confidence 7/10

Negative free cash flow offset by strong analyst backing and upcoming pipeline catalysts suggest near-term upside for CNTA.

Dec 11, 2025CNTA

Stock Weather AIBiotechnologyHealthcare

Rhythm Pharmaceuticals – 2025-12-11 - Increase Confidence 6/10

Strong gross margin and analyst buy consensus clash with negative free cash flow; no direct news catalyst, but biotech sentiment may lift RYTM in short term.

Dec 11, 2025RYTM

Stock Weather AIBiotechnologyClinical Trials

Wave Life Sciences – 2025-12-11 - Increase Confidence 8/10

Despite negative cash flow, a $250M capital raise and positive Phase 1 obesity drug data catalyze near-term upside momentum.

Dec 11, 2025WVE

Stock Weather AIBiotechnologyClinical-Stage Biopharma

Denali Therapeutics – 2025-12-10 - Increase Confidence 6/10

Negative free cash flow and high debt are offset by a $200M capital raise and bullish analyst targets, signaling near-term upside potential.

Dec 10, 2025DNLI

Stock Weather AIBiotechnologyClinical-Stage Stocks

Wave Life Sciences – 2025-12-09 - Increase Confidence 8/10

Strong analyst momentum and positive Phase 1 weight-loss data outweigh near-term cash burn, signaling upside in WVE.

Dec 9, 2025WVE

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-12-08 - Increase Confidence 9/10

Negative free cash flow offset by strong trial data and cash runway, triggering near-term upside momentum.

Dec 8, 2025GPCR

Stock Weather AIBiotechnologyClinical-Stage Pharma

Kymera Therapeutics – 2025-12-08 - Increase Confidence 8/10

Negative free cash flow offset by strong cash runway and recent pipeline catalysts; first patient dosed in Phase 2b trial drives near-term upside.

Dec 8, 2025KYMR

Stock Weather AIBiotechnologyAnalyst Sentiment

Legend Biotech – 2025-12-08 - Increase Confidence 6/10

Despite negative free cash flow and ultra-expensive valuation, overwhelming Carvykti demand and strong analyst consensus signal near-term upside.

Dec 8, 2025LEGN

Stock Weather AIBiotechnologyClinical Trials

Terns Pharmaceuticals – 2025-12-08 - increase Confidence 8/10

Strong cash runway into 2028 meets breakthrough Phase 1 data showing 75% MMR in CML, fueling near-term upside for TERN.

Dec 8, 2025TERN

Stock Weather AIBiotechnologyClinical-Stage Pharma

Wave Life Sciences – 2025-12-08 - Increase Confidence 7/10

Positive pipeline data and strong analyst sentiment outweigh near-term dilution risk from $250M share offering, signaling short-term upside.

Dec 8, 2025WVE

AI NewsQuantum ComputingBiotechnology

Quantum Entanglement Detection Breakthrough at LHC and €27.5M Funding for Photonic Chips

Quantum entanglement detection at LHC and €27.5M funding for photonic chips drive quantum tech scaling.

Dec 6, 2025

Stock Weather AIBiotechnologyClinical Trials

Praxis Precision Medicines – 2025-12-05 - Increase Confidence 8/10

Negative free cash flow offset by $567M capital raise and positive Phase 3 data for ulixacaltamide drive near-term upside potential.

Dec 5, 2025PRAX

AI NewsBiotechnologyClimate Resilience

AlphaFold Enables Heat-Resilient Crops via GLYK Enzyme Engineering

AlphaFold predicts GLYK enzyme structures, enabling heat-tolerant crops stable at 65°C.

Dec 4, 2025

Stock Weather AIBiotechnologyClinical Catalysts

Beam Therapeutics – 2025-12-04 - Increase Confidence 8/10

Strong cash runway and upcoming ASH data catalyst for BEAM-101 drive near-term upside potential despite negative free cash flow.

Dec 4, 2025BEAM

Stock Weather AIBiotechnologyClinical Trials

Spyre Therapeutics – 2025-12-04 - Increase Confidence 7/10

Strong cash infusion from recent offering combined with first patient enrollment in Phase 2 SKYWAY trial signals near-term momentum, supporting stock price increase.

Dec 4, 2025SYRE